IL6 and hepatocellular carcinoma: In a previous study, expressions of lnc-DILC were suppressed in HCC patients and were correlated with IL-6 and CD24 levels, suggesting that lnc-DILC is a potential prognostic biomarker and therapeutic target against liver CSCs33.